KR101277004B1 - 초분자 구조체를 포함하는 방법 및 조성물 - Google Patents

초분자 구조체를 포함하는 방법 및 조성물 Download PDF

Info

Publication number
KR101277004B1
KR101277004B1 KR1020127019675A KR20127019675A KR101277004B1 KR 101277004 B1 KR101277004 B1 KR 101277004B1 KR 1020127019675 A KR1020127019675 A KR 1020127019675A KR 20127019675 A KR20127019675 A KR 20127019675A KR 101277004 B1 KR101277004 B1 KR 101277004B1
Authority
KR
South Korea
Prior art keywords
peptide
composition
antigenic
peg
antibodies
Prior art date
Application number
KR1020127019675A
Other languages
English (en)
Korean (ko)
Other versions
KR20120097546A (ko
Inventor
이브스 크라우드 니코라우
루쓰 그레페라쓰
데이비드 히크만
Original Assignee
에이씨 이뮨 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/783,975 external-priority patent/US20040242845A1/en
Priority claimed from US10/958,211 external-priority patent/US8663650B2/en
Application filed by 에이씨 이뮨 에스.에이. filed Critical 에이씨 이뮨 에스.에이.
Publication of KR20120097546A publication Critical patent/KR20120097546A/ko
Application granted granted Critical
Publication of KR101277004B1 publication Critical patent/KR101277004B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127019675A 2004-02-20 2005-02-22 초분자 구조체를 포함하는 방법 및 조성물 KR101277004B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/783,975 US20040242845A1 (en) 2003-02-21 2004-02-20 Methods and compositions comprising supramolecular antigenic constructs and antibodies elicited against them
US10/783,975 2004-02-20
US10/958,211 US8663650B2 (en) 2003-02-21 2004-10-04 Methods and compositions comprising supramolecular constructs
US10/958,211 2004-10-04
PCT/US2005/005285 WO2005081872A2 (en) 2004-02-20 2005-02-22 Methods and compositions comprising supramolecular constructs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020067019374A Division KR101208173B1 (ko) 2004-02-20 2005-02-22 초분자 구조체를 포함하는 방법 및 조성물

Publications (2)

Publication Number Publication Date
KR20120097546A KR20120097546A (ko) 2012-09-04
KR101277004B1 true KR101277004B1 (ko) 2013-06-24

Family

ID=46395388

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127019675A KR101277004B1 (ko) 2004-02-20 2005-02-22 초분자 구조체를 포함하는 방법 및 조성물

Country Status (11)

Country Link
JP (1) JP4934433B2 (ru)
KR (1) KR101277004B1 (ru)
CY (1) CY1116316T1 (ru)
DK (1) DK2465533T3 (ru)
ES (2) ES2385226T3 (ru)
HK (2) HK1130698A1 (ru)
HR (1) HRP20150612T1 (ru)
HU (1) HUE025186T2 (ru)
PT (1) PT2465533E (ru)
RS (1) RS54074B1 (ru)
SI (1) SI2465533T1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010224824B2 (en) * 2009-03-18 2014-02-20 Ac Immune S.A. Method for therapeutic use
CN103189050B (zh) * 2010-10-26 2017-09-29 Ac免疫有限公司 包含通过疏水部分修饰的肽的基于脂质体的构建体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999041279A2 (en) 1998-02-13 1999-08-19 Arch Development Corporation Methods and compositions comprising the use of blocked b-amyloid peptide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187335B1 (en) * 1997-12-31 2001-02-13 Orasomal Technologies, Inc. Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
EP1259563B2 (en) * 1999-12-22 2016-08-10 Nektar Therapeutics Method for the preparation of 1-benzotriazolyl carbonate esters of water soluble polymers.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999041279A2 (en) 1998-02-13 1999-08-19 Arch Development Corporation Methods and compositions comprising the use of blocked b-amyloid peptide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
International Jouranl of Pharmaceutics, vol. 254, pp. 55-58, 2003. *
PNAS, vol. 99, no. 4, pp. 2332-2337, 2002. *

Also Published As

Publication number Publication date
PT2465533E (pt) 2015-06-24
HUE025186T2 (en) 2016-02-29
ES2385226T3 (es) 2012-07-19
DK2465533T3 (en) 2015-04-20
ES2385226T9 (es) 2013-10-10
CY1116316T1 (el) 2017-02-08
HK1172260A1 (en) 2013-04-19
SI2465533T1 (sl) 2015-07-31
HRP20150612T1 (hr) 2015-07-03
JP4934433B2 (ja) 2012-05-16
JP2007527870A (ja) 2007-10-04
HK1130698A1 (en) 2010-01-08
KR20120097546A (ko) 2012-09-04
RS54074B1 (en) 2015-10-30
ES2539262T3 (es) 2015-06-29

Similar Documents

Publication Publication Date Title
US9975946B2 (en) Antibodies obtainable using supramolecular constructs
JP5249043B2 (ja) 治療ワクチン
ES2368907T3 (es) Procedimientos y composiciones inmunológicas para el tratamiento de la enfermedad de alzheimer.
RU2551782C2 (ru) Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
JP2012522754A (ja) 薬学的組成物
JP2015221809A (ja) 治療的使用のための方法
US20040242845A1 (en) Methods and compositions comprising supramolecular antigenic constructs and antibodies elicited against them
KR101277004B1 (ko) 초분자 구조체를 포함하는 방법 및 조성물
JP2007527870A5 (ru)
PFEIFER et al. Sommaire du brevet 2633399

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20160525

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20170525

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20180521

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20190514

Year of fee payment: 7